Mo .. First apologies for my delayed response

Mo ..

First apologies for my delayed response .. was away for the past 3 days for a long planned for family event .. and there is never enough time in the day some days ..

One of the aspects of observing/documenting OTC *activity* is the learning that comes from that in conjunction with making phone calls .. not just to company IRs .. or Finra or the SEC .. but to TA (transfer agents) too .. something i've done for years

The way it usually works when shares are issued to an entity .. is the monies are first collected by the TA .. then the cert is cut and then transferred .. that is why imo while *shares* can be worked off in advance of issuance and transfer by the usual suspects .. we see a timeline *imo* re: IPIX *volume* kick in on the 9th of April .. it's also very telling *imo* that mgmt got in front of *imo* >> a *known* perceived negative (shares potentially hitting the tape) and 8k'd the PR issued on 4.9.18 .. (see below)

now what some may or may not know .. is you can see what is reported by actual MMs to Finra every month .. this data comes out usually by about the 7th to 10th of the following month ..

(remember tho' date noted in filing
was 4.1.18 .. that was a Sunday .. with first *potential* date for selling on 4.2.18 .. which imo was not reality based on the usual time lines known and tapes of trades for that first week and volume for 10 day noted on the morning of 4.9.18 at just over 90,000)

4.9.2018 .. IPIX Volume 382,840
Volume (10 Day Average) 90,757
Volume (90 Day Average) 246,670

MMs' MM Monthly April 2018 reported 4,473,436 .. now the way this works is to cut that number in half .. because half of total reported are shares bought and half of what are reported are shares sold ( 4,473,436 divided by 2 = 2,236,718 )

http://otce.finra.org/MonthlyShareVolume

https://finance.yahoo.com/quote/IPIX/history?...equency=1d

since the start of May .. (yahoo will round off) .. so I went back to my screenshots and pulled each day's data since May 1st thru Friday (5.11.18) .. for actual numbers


5.1.2018 .. IPIX Volume 191,629
Volume (10 day Average) 266,416
Volume (90 day Average) 211,766

5.2.2018 .. IPIX Volume 248,670
Volume (10 day Average) 258,993
Volume (90 day Average) 211,429

5.3.2018 .. IPIX Volume 161,353
Volume (10 day Average) 256,793
Volume (90 day Average) 211,136

5.4.2018 .. IPIX Volume 200,005
Volume (10 day Average) 222,038
Volume (90 day Average) 211,292

5.7.2018 .. IPIX Volume 578,397
Volume (10 Day Average) 211,721
Volume (90 Day Average) 211,839

5.8.2018 .. IPIX Volume 185,071
Volume (10 day Average) 235,332
Volume (90 day Average) 216,329

5.9.2018 .. IPIX Volume 655,074
Volume (10 day Average) 229,990
Volume (90 day Average) 213,938

5.10.2018 .. IPIX Volume 522,474
Volume (10 day Average) 281,349
Volume (90 day Average) 217,466

5.11.2018 .. IPIX Volume 360,275
Volume (10 day Average) 319,602
Volume (90 day Average) 220,187

I show Volume total currently for May 2018 based on the above = 3,102,948 .. divided by 2 = 1551,474 ..

1,551,474 (May currently) + 2,236,718 for April 2018 = 3,788,192 *sells*

Realize that that may not be all the one entity selling .. note the *high* re: PPS achieved on 4.9.18 (63c and the most recent *high* on IPIX for weeks) .. *imo* first day of entity selling (again entity's known awareness of *access* to those forthcoming shares allows for all sorts of games to be played out) .. we see the PPS taken to 63c .. pre reset back down .. the day mgmt 8k'd this PR .. volume that day with a *liquidity* range of 8c *imo* allows for the possibility of those who trade also being in play then

Apr 09, 2018 0.61 0.63 0.55 0.58 0.58 391,300

April 9, 2018
INNOVATION PHARMACEUTICALS PHASE 2 ORAL MUCOSITIS TRIAL ADDITIONAL DATA SHOW BRILACIDIN-OM DEMONSTRATED A SIGNIFICANT REDUCTION IN THE INCIDENCE OF SEVERE ORAL MUCOSITIS...

http://www.ipharminc.com/press-release/

so entity has a ways to go *imo* based on 8M *available* and known sells of (possibly and probably not all of theirs) 3,788,192 by COM on 5.11.18 .. entity may not *sell* every *share* available .. based on what Mgmt noted subsequent to 4.9.18

May 9, 2018
INNOVATION PHARMACEUTICALS CONCLUDES DATA ANALYSIS OF ITS PHASE 2 CLINICAL TRIAL FOR SEVERE ORAL MUCOSITIS IN HEAD AND NECK CANCER; POSITIONING TO FILL A SUBSTANTIAL VOID IN SUPPORTIVE CANCER CARE

April 23, 2018
INNOVATION PHARMACEUTICALS SIGNS DRUG SUPPLY CONTRACT WITH EVONIK TO BULK PRODUCE COMMERCIAL-GRADE BRILACIDIN

April 16, 2018
INNOVATION PHARMACEUTICALS DATA FROM PHASE 2 BRILACIDIN ORAL MUCOSITIS (OM) TRIAL IN HEAD AND NECK CANCER SHOW NOTABLE REDUCTIONS IN MEDIAN DURATION OF SEVERE OM AND IN NUMBER OF UNPLANNED VISITS...

and filed ..

http://www.ipharminc.com/financials/

one last fact .. re: data that has always threatened NR since link first went live back in Feb 2010 .. having noted this data since i first invested in this *imo* OTC Survivor .. since 4.2.18 .. the *days that IPIX has been marked*

@ sub 30% are 3

the days that IPIX has been marked

@ plus 30% are 12
@ plus 40% are 9 (including 5/9 and 5/11)
@ plus 50% are 6 (including 5/8 and 5/10)

out of those 30 days (total) .. i am not including the handful of days that pre mkt or ah trades went off .. that do bypass those %s being *marked* by MMs ..

%s having to be *marked* higher are morphing up the food chain .. something when understood in aggregate and in comparison to prior *time lines and NR efforts* is understandable as to why it threatens

i hope this helps .. i'd planned to expound on *imo* a few options MMs may undertake on IPIX going forward ..

i did not see most of Friday's *trading* live as i was traveling .. but i can watch today and will see if one of the 3 options i'd noted in this venue previously looks to be in play ..

this is what i refer to a *partially laddered take up* .. when % reset back down is less than the % reset back up .. imo in NRs' *shoes* .. it's the option i'd undertake

if this is the option chosen by NR .. we will still see a significant % marked each day and *legal* short reported .. imo will remain hovering along @ the 1M to 1.3M

*legal* (dated data) next report due out ah's on 5.24.18

http://www.finra.org/industry/short-interest/...-due-dates


4kids

Quote:

---

Please check my math on shares sold from 4/2/18 thru 5/9/18. I added up the total shares sold on the attached from 4kids and it came out to 6,690,500 shares sold. 4kids also mentions that the following volumes as of 5/9/18.
Volume (10 day Average) 229,990
Volume (90 day Average) 213,938

Per the 10Q IPIX sold 8M shares or an average of 285,714 shares/day through Aspire in that same period. I realize that none of us know the exact amount that Aspire sold on the open market but as mentioned by Sox, we know that Aspire has never filed a 13G indicating they own less than 5% or 7M shares of IPIX stock. The stock price dropped 30% from .51 to .36 during this period. So we know that Aspire held on to at least 1.3M shares (8M-6.69M) but represented a vast majority of the supply of shares available for sale during this period.
I am not stating that I don’t believe there are not criminal entities trying to cripple IPIX, as it is obvious that some entity with deep pockets has been funding the manipulation of the stock price going back to the orchestrated Mako/Rosen attack and has continued to date There are obvious shorting cabals but these guys are small players in the big picture and are again probably being paid off by an entity that either has competing drugs or is trying to buy IPIX assets cheaply. So to those that have argued whether it has been Aspire pressure on a thinly traded pre-revenue stock vs those that believe illegal activities including NSS, my position is that you are both right. It has been a layup for the short sellers UP TO THIS POINT. Science wins at the end and a partnership is a validation stamp and the end of dilution.
It has been painful to watch the share price spiral downward but there have been several “tells” that IPIX has communicated that tell me that:
- A B-OM deal is as good as done (negotiation stage) and will be finalized after the P results are known.
- P results have very good odds of being positive and there could be a P partnership very soon as well.
- Either of the above or possibly both will make the Aspire deal unnecessary going forward. (No more dilution)
- IPIX is exploring new facilities for corporate Headquarters. Over the next year company plans on increasing all areas of administration to include employees and facilities. If you were CEO why would you possibly do this unless you were positioning for major growth?
- IPIX has $2M in the bank ($1.3M cash plus $2M Aspire sales less $1M owed to CRO) and Leo has delayed any unnecessary expenditures.
- Evonik deal in place to produce B-OM packaging and probable B-UP foam etc. Would you sign a drug manufacturing contract if a deal wasn’t close?
- I haven’t even mentioned K which if successful could make IPIX a triple digit stock.
For a more complete list regarding the science check out posts by Drano, Sox, DaubersUP and others. The next few weeks should be exciting . GLTA longs,

---